<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03518125</url>
  </required_header>
  <id_info>
    <org_study_id>BP-C-17001</org_study_id>
    <secondary_id>HHSO100201400004I</secondary_id>
    <nct_id>NCT03518125</nct_id>
  </id_info>
  <brief_title>BARDA Securing Anthrax Immunity For the Elderly</brief_title>
  <acronym>B-SAFE</acronym>
  <official_title>Randomized, Active-Comparison, Double-Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Anthrax Vaccine Adsorbed (BioThrax®) Without and With CPG 7909 Adjuvant (AV7909 Anthrax Vaccine), Using a Post-Exposure Prophylaxis Dosing Regimen in Adults 66 Years of Age or Older in Stable Health in Comparison to Adults 18-50 Years of Age in Stable Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rho, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biomedical Advanced Research and Development Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety and ability of BioThrax and AV7909 anthrax
      vaccines to generate an immune response in adults ≥ 66 years of age in stable health in
      comparison to adults 18-50 years of age in stable health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2, randomized, active-controlled, double-blinded, multi-site study to assess
      the safety and immunogenicity of BioThrax (Anthrax Vaccine Adsorbed) and AV7909 (Anthrax
      Vaccine Adsorbed plus CPG 7909 adjuvant) using a post-exposure prophylaxis dosing regimen in
      adults ≥ 66 years of age in stable health. The safety and immunogenicity profile of BioThrax
      and AV7909 in adults ≥ 66 years of age will also be compared to the safety and immunogenicity
      profile of subjects 18-50 years of age in stable health. The main study goal is to determine
      optimal dosing for AV7909 in the elderly population. Subjects will receive either 3 doses of
      BioThrax, 3 doses of AV7909, or 2 doses of AV7909 and 1 dose of placebo. Doses will be
      administered approximately 14 days apart. Subjects will be followed for safety assessment for
      12 months following the last dose. The expected study duration is approximately 14 months per
      subject.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Actual">December 9, 2019</completion_date>
  <primary_completion_date type="Actual">January 14, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to receive either BioThrax or AV7909. Randomization will be stratified by sex and age (18-50, 66-74, and ≥75 years). Subjects ≥66 years of age will be randomized 1:1:1:1 within stratum across 4 treatment arms (approximately 50 subjects per group), and subjects 18 through 50 years of age will be randomized 1:1 within stratum across 2 treatment arms (approximately 50 subjects per group). Once randomized, subjects will receive 3 vaccinations, each separated by approximately 14 days, on Day 1, Day 15, and Day 29, based on their assigned treatment arm.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited Local Reactogenicity Symptoms</measure>
    <time_frame>Day 1-8, Day 15-22, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)</time_frame>
    <description>Count of participants who experienced at least one of the following during the time frame specified on the arm which received the vaccination: injection site warmth, tenderness, itching, pain, restriction of range of arm motion, erythema/redness, palpable or observable lump, induration/swelling, or bruising.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited Systemic Reactogenicity Symptoms</measure>
    <time_frame>Day 1-8, Day 15-22, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)</time_frame>
    <description>Count of participants who experienced at least one of the following during the time frame specified on the arm which received the vaccination: fatigue, myalgia/muscle ache, headache, and fever.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Based on Toxin Neutralization Antibody (TNA) 50% Neutralization Factor (NF50) Antibody Level, Defined as a TNA NF50 Antibody Level ≥0.56</measure>
    <time_frame>Day 64</time_frame>
    <description>The percentage of participants achieving seroprotection based on TNA NF50. A 70% probability of survival was associated with a TNA NF50 level of 0.56 in rabbits exposed to Bacillus anthracis, the bacteria that causes anthrax.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Day 1 through Day 394</time_frame>
    <description>The count of participants who experienced at least one post-vaccination unsolicited AE (i.e. AEs not included in the solicited local and systemic adverse event list through Day 50 and those reported as a serious AE, medically attended adverse event (MAAE), or potentially immune-mediated medical condition (PIMMC) after Day 50).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 through Day 394</time_frame>
    <description>The count of participants who experienced at least one post-vaccination SAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Medically Attended Adverse Events (MAAEs)</measure>
    <time_frame>Day 1 through Day 394</time_frame>
    <description>Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs)</measure>
    <time_frame>Day 1 through Day 394</time_frame>
    <description>Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited Local Reactogenicity Symptoms on the Contralateral Arm</measure>
    <time_frame>Day 1-8, Day 15-22, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)</time_frame>
    <description>Count of participants who experienced at least one of the following during the time frame specified on the arm which did not receive the vaccination: injection site warmth, tenderness, itching, pain, restriction of range of arm motion, erythema/redness, palpable or observable lump, induration/swelling, or bruising.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNA NF50 Antibody Levels</measure>
    <time_frame>Days 1, 8, 22, 29, 36, 43, 50, 64, 85, 181, and 394</time_frame>
    <description>A higher TNA NF50 antibody level means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNA Effective Dilution Resulting in 50% Neutralization (ED50) Antibody Levels</measure>
    <time_frame>Days 1, 8, 22, 29, 36, 43, 50, 64, 85, 181, and 394</time_frame>
    <description>A higher TNA ED50 antibody level means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enzyme-linked Immunosorbent Assay (ELISA) Anti-protective Antigen (Anti-PA) Immunoglobulin G (IgG) Antibody Levels</measure>
    <time_frame>Days 1, 8, 22, 29, 36, 43, 50, 64, 85, 181, and 394</time_frame>
    <description>A higher ELISA anti-PA IgG antibody level means a better immune response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Based on TNA NF50, Defined as a TNA NF50 Antibody Level ≥0.56</measure>
    <time_frame>Days 1, 8, 22, 29, 36, 43, 50, 85, 181, and 394</time_frame>
    <description>The percentage of participants achieving seroprotection based on TNA NF50 antibody level. A 70% probability of survival was associated with a TNA NF50 level of 0.56 in rabbits exposed to Bacillus anthracis, the bacteria that causes anthrax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Based on TNA NF50, Defined as a ≥4-fold Increase Over Pre-vaccination Levels, or a ≥4-fold Increase Over the Lower Limit of Quantification (LLOQ) if the Pre-vaccination Value is Below the LLOQ</measure>
    <time_frame>Days 8, 22, 29, 36, 43, 50, 64, 85, 181, and 394</time_frame>
    <description>The percentage of subjects obtaining seroconversion based on TNA NF50 antibody levels. Seroconversion represents the minimum intended effect of vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Based on TNA ED50, Defined as a ≥4-fold Increase Over Pre-vaccination Levels, or a ≥4-fold Increase Over the Lower Limit of Quantification (LLOQ) if the Pre-vaccination Value is Below the LLOQ</measure>
    <time_frame>Days 8, 22, 29, 36, 43, 50, 64, 85, 181, and 394</time_frame>
    <description>The percentage of subjects obtaining seroconversion based on TNA ED50 antibody levels. Seroconversion represents the minimum intended effect of vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Based on ELISA Anti-PA IgG, Defined as a ≥4-fold Increase Over Pre-vaccination Levels, or a ≥4-fold Increase Over the Lower Limit of Quantification (LLOQ) if the Pre-vaccination Value is Below the LLOQ</measure>
    <time_frame>Days 8, 22, 29, 36, 43, 50, 64, 85, 181, and 394</time_frame>
    <description>The percentage of subjects obtaining seroconversion based on ELISA anti-PA IgG antibody levels. Seroconversion represents the minimum intended effect of vaccination.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">305</enrollment>
  <condition>Anthrax</condition>
  <arm_group>
    <arm_group_label>Age ≥ 66, BioThrax (Days 1, 15, 29)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age ≥ 66, AV7909 (Days 1, 15, 29)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects dosed on Days 1, 15, and 29 with 0.5 mL AV7909.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age ≥ 66, AV7909 (Days 1 and 15)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age ≥ 66, AV7909 (Days 1 and 29)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects dosed on Days 1 and 29 with 0.5 mL AV7909 and on Day 15 with 0.5 mL placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age18-50, BioThrax (Days 1, 15, 29)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age 18-50, AV7909 (Days 1 and 15)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BioThrax</intervention_name>
    <description>Other Names:
Anthrax Vaccine Adsorbed (AVA)</description>
    <arm_group_label>Age ≥ 66, BioThrax (Days 1, 15, 29)</arm_group_label>
    <arm_group_label>Age18-50, BioThrax (Days 1, 15, 29)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AV7909</intervention_name>
    <description>Anthrax Vaccine Absorbed plus CPG 7909 Adjuvant</description>
    <arm_group_label>Age 18-50, AV7909 (Days 1 and 15)</arm_group_label>
    <arm_group_label>Age ≥ 66, AV7909 (Days 1 and 15)</arm_group_label>
    <arm_group_label>Age ≥ 66, AV7909 (Days 1 and 29)</arm_group_label>
    <arm_group_label>Age ≥ 66, AV7909 (Days 1, 15, 29)</arm_group_label>
    <other_name>AV7909 Anthrax Vaccine Adsorbed</other_name>
    <other_name>NuThrax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride injection USP, 0.9% (placebo)</intervention_name>
    <description>Other Names:
Saline Solution</description>
    <arm_group_label>Age 18-50, AV7909 (Days 1 and 15)</arm_group_label>
    <arm_group_label>Age ≥ 66, AV7909 (Days 1 and 15)</arm_group_label>
    <arm_group_label>Age ≥ 66, AV7909 (Days 1 and 29)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or nonpregnant females, 66 years of age or older at the time of randomization for
             the elderly population, or 18 through 50 years of age at the time of randomization for
             the younger population.

          2. Females who are of childbearing potential and are sexually active with a male partner
             must agree to use an acceptable method of birth control from Screening to Day 64 and
             must have used a reliable birth control method for at least 2 months prior to
             Screening.

               1. A female of childbearing potential is defined as post onset menarche and
                  pre-menopausal female capable of becoming pregnant. This does not include females
                  who meet any of the following conditions: menopausal &gt;2 years, tubal ligation &gt;1
                  year, bilateral salpingo-oophorectomy, or hysterectomy.

               2. Adequate contraception is defined as a contraceptive method with a failure rate
                  of less than 1% per year when used consistently and correctly and when
                  applicable, in accordance with the product label. Examples include: oral
                  contraceptives, either combined or progestogen alone; injectable progestogen;
                  implants of etenogestrel or levonorgestrel; estrogenic vaginal ring; percutaneous
                  contraceptive patches; intrauterine device or intrauterine system; male partner
                  sterilization at least 6 months prior to the female subject's Screening Visit,
                  and this male is the sole partner for that subject (the information on the male
                  partner's sterility can come from the site personnel's review of the subject's
                  medical records or interview with the subject on her medical history); male
                  condom combined with a vaginal spermicide (foam, gel, film, cream, or
                  suppository); male condom combined with a female diaphragm, either with or
                  without a vaginal spermicide (foam, gel, film, cream, or suppository).

          3. Able to provide written informed consent prior to initiation of any study procedures.
             As part of the consent process, subjects must be able to demonstrate understanding by
             passing the &quot;Assessment of Understanding Questionnaire&quot; within 2 attempts. Passing is
             defined as being able to answer all questions correctly.

          4. In relatively stable health based on site investigator's judgment, as determined by
             medical history, physical examination, and the following criteria:

               1. Stable health for age (defined as no new conditions per medical history, new
                  medications in a different therapeutic class, or change in daily dose of existing
                  prescription medications within the 45 days preceding Screening). Effective
                  treatment (to resolution) of an acute infection (e.g., urinary tract infection,
                  cellulitis, otitis, or bronchitis) with an antibiotic within 45 days preceding
                  Screening will not be considered a deviation from this inclusion criterion as
                  long as the antibiotic therapy was completed at least one week prior to Screening
                  and no signs or symptoms of the infection have been present since the completion
                  of treatment. Any prescription change that is due to change of health care
                  provider or insurance company, or that is made for reasons that do not reflect a
                  change in disease status (e.g., financial considerations), as long as within the
                  same general class of medication, will not be considered a deviation from this
                  inclusion criterion. Any change in prescription medication due to improvement of
                  a disease outcome, as determined by the site investigator, will not be considered
                  a deviation from this inclusion criterion.

               2. Subjects may be on chronic or as needed (prn) medications if, in the opinion of
                  the site investigator, these pose no additional risk to subject safety or
                  assessment of reactogenicity and immunogenicity and their use is not for
                  management of a worsening of medical diagnosis or condition. Note: Topical,
                  nasal, and inhaled medications (with the exception of steroids, as outlined in
                  the subject exclusion criteria) and vitamins are permitted.

          5. Have a body mass index (BMI) less than 35.0 kg/m2 at Screening. (BMI will not be
             reassessed prior to subsequent vaccinations.)

          6. Have access to a consistent and reliable means of telephone contact, which may be
             home, workplace, or by personal mobile electronic device.

          7. Are available and able to comply with all study visits.

        Exclusion Criteria:

          1. Females who have a positive urine pregnancy test at Screening or within 24 hours prior
             to each study vaccination or women who are breastfeeding.

          2. Have a requirement for skilled nursing care.

          3. Have a history of severe reactions to components of AVA or CPG 7909, e.g.,
             formaldehyde, benzethonium chloride (phemerol), or aluminum.

          4. Have a history of latex sensitivity.

          5. Have a history of ever receiving a vaccine for anthrax prior to Screening, or had an
             anthrax infection.

          6. Have any medical, psychiatric, or social condition that, in the opinion of the site
             investigator, unfavorably alters the risk-benefit of subject participation, or is
             likely to interfere with study compliance or assessments, or is likely to confound
             interpretation of safety or immunogenicity data.

          7. Have any diagnosis, current or past, of a potentially immune-mediated medical
             condition, such as Guillain-Barré syndrome, narcolepsy, or an autoimmune or chronic
             inflammatory disease.

          8. Have any diagnosis, current or past, of schizophrenia or bipolar disorder.

          9. Have been hospitalized for psychiatric illness, have a history of suicide attempt, or
             confinement for danger to self or others within the preceding 10 years prior to
             Screening and each study vaccination.

         10. Have a history of alcohol or drug abuse (per investigator's judgment) within 5 years
             prior to Screening and each study vaccination, or test positive for drugs of abuse at
             Screening (including for cannabis, even where legal). Benzodiazepines for anxiety
             disorders and stimulants for attention deficit hyperactivity disorder are not
             exclusionary if the subject has been on a stable dose for more than 3 months prior to
             Screening and each study vaccination and if the subject can produce a valid, current
             prescription for the medication. Propoxyphene, opioids, or combinations containing
             these medications (including as used for opioid addiction) are not permitted
             regardless of prescription status. Note: A positive Screening urine drug screen may
             not be repeated. (Drug screen will not be repeated prior to subsequent vaccinations.)

         11. Have known human immunodeficiency virus (HIV), or acute or chronic hepatitis B or
             hepatitis C infection based on medical history; or test positive for any of these at
             Screening. Subjects who have been effectively treated for hepatitis C, as evidenced by
             a negative hepatitis C ribonucleic acid (RNA) confirmation test and who no longer
             require antiviral therapy, are eligible for participation. (Screening tests will not
             be repeated prior to subsequent vaccinations.)

         12. Have known active neoplastic disease or a history of any hematologic malignancy.
             However, subjects with superficial skin cancer who do not require intervention other
             than local excision are not excluded.

         13. Have immunosuppression as a result of an underlying illness or treatment, or use of
             anticancer chemotherapy (cytotoxic) or radiation therapy within 3 years prior to
             Screening and each study vaccination.

         14. Have taken any systemic immunosuppressive agents, including immunomodulators, 6 months
             prior to Screening and each study vaccination. Allergen immunotherapy
             (desensitization) is not exclusionary. Allergen immunotherapy (desensitization) does
             not include systemic antibodies such as benralizumab, mepolizumab, or omalizumab;
             these are exclusionary.

         15. Are suffering from or have a history of neuralgia, paresthesia, or neuritis within 90
             days prior to Screening and each study vaccination; or have any history of stroke.

         16. Have had convulsions or encephalomyelitis within three years prior to Screening and
             each study vaccination.

         17. Have received immunoglobulin or other blood products (with the exception of Rho[D]
             immune globulin) within 90 days prior to Screening and each study vaccination.

         18. Have received an experimental agent within 180 days prior to the first study
             vaccination, or expects to participate in another clinical trial with an
             interventional agent during the study period. This includes licensed or unlicensed
             vaccines, drugs, biologics, devices, blood products, or medications. Participation in
             an observational study is not exclusionary as long as it doesn't interfere with study
             visits or procedures (e.g., blood collection volume restrictions).

         19. Have taken oral or parenteral corticosteroids of any dose within 30 days prior to each
             study vaccination.

         20. Have taken high-dose inhaled corticosteroids within 30 days prior to each study
             vaccination. High-dose is defined as &gt;800 mcg/day of beclomethasone dipropionate or
             equivalent. Lower doses of inhaled corticosteroids are not exclusionary.

         21. Have received any licensed live vaccine within 30 days prior to the first study
             vaccination or planned receipt from the first study vaccination through Visit 10 (Day
             64).

         22. Have received any licensed inactivated vaccine within 14 days prior to the first study
             vaccination or planned receipt from the first study vaccination through Visit 10 (Day
             64).

         23. Have an acute illness, as determined by the site investigator, within 72 hours prior
             to each study vaccination.

               1. If subject's oral temperature is above 100.0°F (37.8°C), the subject may be
                  re-assessed for eligibility within the visit window (+3 Days).

               2. An acute illness that is nearly resolved, with only minor residual symptoms
                  remaining, is allowable if, in the opinion of the site investigator, the residual
                  symptoms will not interfere with the ability of study staff to assess safety
                  parameters as required by the protocol.

               3. For bacterial infections that have been successfully treated with antibiotics,
                  inclusion criterion 4a applies.

         24. Have a history of myocardial infarction or ischemia, or have electrocardiogram (ECG)
             findings of myocardial infarction, ischemia, strain, complete bundle branch block, or
             ventricular arrhythmias (other than unifocal premature ventricular contractions
             ≤2/minute). Additionally, other cardiac history or ECG findings, which in the opinion
             of the investigator represent a potentially unstable or unacceptably high risk of an
             adverse cardiac outcome, are exclusionary. (ECG will not be repeated prior to
             subsequent vaccinations.)

         25. Have any laboratory test result or clinical findings (including vital signs) that
             singly or in combination are, in the investigator's opinion, likely to unfavorably
             alter the risk-benefit of subject participation or to confound study safety or
             immunogenicity results. Additionally, the following are exclusionary:

               1. Any clinically significant Grade 3 laboratory or vital sign result, or any Grade
                  4 laboratory or vital sign result (regardless of assessed significance) at
                  Screening. For subsequent vaccinations, abnormal laboratory results and vital
                  sign results postvaccination will be assessed against the rules for early
                  termination of dosing.

               2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2 times the
                  upper limit of normal (ULN), or bilirubin &gt;1.5 times the ULN unless isolated
                  Gilbert's syndrome.

               3. Creatinine &gt;1.5 times ULN for age and sex.

               4. White blood cell count &lt;3,000/μL or &gt;12,500/μL; absolute neutrophil count
                  &lt;1200/μL; absolute lymphocyte count &lt;750/μL; hemoglobin &lt;10 g/dL females, or
                  &lt;11.5 g/dL males; platelet count &lt;75,000/μL.

               5. Hemoglobin A1C (HbA1C) &gt;7.0% at Screening. (HbA1C will not be repeated prior to
                  subsequent vaccinations.)

        Subjects cannot be rescreened for exclusionary laboratory test results. Potentially
        exclusionary vital sign results may be repeated, but unless they have resolved to a Grade 3
        designation or less and are not considered clinically significant, the subject should be
        excluded. The most recent laboratory and vital sign results will be used when determining
        eligibility for subsequent vaccinations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Fierro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johnson County Clin-Trials</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Derek Muse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JBR Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Sharp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Associates, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cynthia Strout, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coastal Carolina Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JBR Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <results_first_submitted>May 18, 2020</results_first_submitted>
  <results_first_submitted_qc>May 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2020</results_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anthrax</keyword>
  <keyword>Bacillaceae Infections</keyword>
  <keyword>Gram-Positive Bacterial Infections</keyword>
  <keyword>Bacterial Infections</keyword>
  <keyword>Anthrax Vaccine Adsorbed</keyword>
  <keyword>BioThrax</keyword>
  <keyword>AV7909</keyword>
  <keyword>CPG 7909</keyword>
  <keyword>Adjuvant</keyword>
  <keyword>Vaccines</keyword>
  <keyword>Post-exposure Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anthrax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03518125/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03518125/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>469 participants were screened at 4 sites in the US between May 14, 2018 – November 8, 2018, of which 305 were randomized and vaccinated between May 17, 2018 – November 12, 2018.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, and Day 29)</title>
          <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
        </group>
        <group group_id="P2">
          <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
          <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
        </group>
        <group group_id="P3">
          <title>Age ≥ 66 Years: AV7909 (Days 1, Day 15) With Placebo (Day 29)</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
        </group>
        <group group_id="P4">
          <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
        </group>
        <group group_id="P5">
          <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
          <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
        </group>
        <group group_id="P6">
          <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="52"/>
                <participants group_id="P6" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="48"/>
                <participants group_id="P6" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Day 394 Visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
      <group_list>
        <group group_id="B1">
          <title>Age ≥ 66 Years: BioThrax (Day1, Day 15, Day 29)</title>
          <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
        </group>
        <group group_id="B2">
          <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
          <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
        </group>
        <group group_id="B3">
          <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
        </group>
        <group group_id="B4">
          <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
        </group>
        <group group_id="B5">
          <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
          <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
        </group>
        <group group_id="B6">
          <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="52"/>
            <count group_id="B5" value="52"/>
            <count group_id="B6" value="52"/>
            <count group_id="B7" value="305"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="51"/>
                    <measurement group_id="B7" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.7" spread="5.89"/>
                    <measurement group_id="B2" value="71.2" spread="4.76"/>
                    <measurement group_id="B3" value="72.8" spread="4.88"/>
                    <measurement group_id="B4" value="72.5" spread="5.04"/>
                    <measurement group_id="B5" value="33.5" spread="9.46"/>
                    <measurement group_id="B6" value="33.7" spread="9.55"/>
                    <measurement group_id="B7" value="59.1" spread="19.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Gender</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="173"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="48"/>
                    <measurement group_id="B7" value="294"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="47"/>
                    <measurement group_id="B7" value="277"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="52"/>
                    <measurement group_id="B7" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Solicited Local Reactogenicity Symptoms</title>
        <description>Count of participants who experienced at least one of the following during the time frame specified on the arm which received the vaccination: injection site warmth, tenderness, itching, pain, restriction of range of arm motion, erythema/redness, palpable or observable lump, induration/swelling, or bruising.</description>
        <time_frame>Day 1-8, Day 15-22, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)</time_frame>
        <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited Local Reactogenicity Symptoms</title>
          <description>Count of participants who experienced at least one of the following during the time frame specified on the arm which received the vaccination: injection site warmth, tenderness, itching, pain, restriction of range of arm motion, erythema/redness, palpable or observable lump, induration/swelling, or bruising.</description>
          <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Solicited Systemic Reactogenicity Symptoms</title>
        <description>Count of participants who experienced at least one of the following during the time frame specified on the arm which received the vaccination: fatigue, myalgia/muscle ache, headache, and fever.</description>
        <time_frame>Day 1-8, Day 15-22, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)</time_frame>
        <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited Systemic Reactogenicity Symptoms</title>
          <description>Count of participants who experienced at least one of the following during the time frame specified on the arm which received the vaccination: fatigue, myalgia/muscle ache, headache, and fever.</description>
          <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Based on Toxin Neutralization Antibody (TNA) 50% Neutralization Factor (NF50) Antibody Level, Defined as a TNA NF50 Antibody Level ≥0.56</title>
        <description>The percentage of participants achieving seroprotection based on TNA NF50. A 70% probability of survival was associated with a TNA NF50 level of 0.56 in rabbits exposed to Bacillus anthracis, the bacteria that causes anthrax.</description>
        <time_frame>Day 64</time_frame>
        <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Based on Toxin Neutralization Antibody (TNA) 50% Neutralization Factor (NF50) Antibody Level, Defined as a TNA NF50 Antibody Level ≥0.56</title>
          <description>The percentage of participants achieving seroprotection based on TNA NF50. A 70% probability of survival was associated with a TNA NF50 level of 0.56 in rabbits exposed to Bacillus anthracis, the bacteria that causes anthrax.</description>
          <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Unsolicited Adverse Events (AEs)</title>
        <description>The count of participants who experienced at least one post-vaccination unsolicited AE (i.e. AEs not included in the solicited local and systemic adverse event list through Day 50 and those reported as a serious AE, medically attended adverse event (MAAE), or potentially immune-mediated medical condition (PIMMC) after Day 50).</description>
        <time_frame>Day 1 through Day 394</time_frame>
        <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Unsolicited Adverse Events (AEs)</title>
          <description>The count of participants who experienced at least one post-vaccination unsolicited AE (i.e. AEs not included in the solicited local and systemic adverse event list through Day 50 and those reported as a serious AE, medically attended adverse event (MAAE), or potentially immune-mediated medical condition (PIMMC) after Day 50).</description>
          <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Serious Adverse Events (SAEs)</title>
        <description>The count of participants who experienced at least one post-vaccination SAE</description>
        <time_frame>Day 1 through Day 394</time_frame>
        <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Serious Adverse Events (SAEs)</title>
          <description>The count of participants who experienced at least one post-vaccination SAE</description>
          <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Medically Attended Adverse Events (MAAEs)</title>
        <description>Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination.</description>
        <time_frame>Day 1 through Day 394</time_frame>
        <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Medically Attended Adverse Events (MAAEs)</title>
          <description>Count of participants who experienced at least one adverse event that requires a visit to medical personnel, including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason occurring post-vaccination.</description>
          <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs)</title>
        <description>Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination</description>
        <time_frame>Day 1 through Day 394</time_frame>
        <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-emergent Potentially Immune Mediated Medical Conditions (PIMMCs)</title>
          <description>Count of participants who experienced at least one medical condition that was potentially immune mediated occurring post-vaccination</description>
          <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Solicited Local Reactogenicity Symptoms on the Contralateral Arm</title>
        <description>Count of participants who experienced at least one of the following during the time frame specified on the arm which did not receive the vaccination: injection site warmth, tenderness, itching, pain, restriction of range of arm motion, erythema/redness, palpable or observable lump, induration/swelling, or bruising.</description>
        <time_frame>Day 1-8, Day 15-22, Day 29-36 (within 8 days of each vaccination, inclusive of the vaccination day)</time_frame>
        <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Solicited Local Reactogenicity Symptoms on the Contralateral Arm</title>
          <description>Count of participants who experienced at least one of the following during the time frame specified on the arm which did not receive the vaccination: injection site warmth, tenderness, itching, pain, restriction of range of arm motion, erythema/redness, palpable or observable lump, induration/swelling, or bruising.</description>
          <population>Safety population includes all randomized participants who received any amount of study vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TNA NF50 Antibody Levels</title>
        <description>A higher TNA NF50 antibody level means a better immune response to the vaccine.</description>
        <time_frame>Days 1, 8, 22, 29, 36, 43, 50, 64, 85, 181, and 394</time_frame>
        <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>TNA NF50 Antibody Levels</title>
          <description>A higher TNA NF50 antibody level means a better immune response to the vaccine.</description>
          <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".03" lower_limit=".03" upper_limit=".03"/>
                    <measurement group_id="O2" value=".03" lower_limit=".03" upper_limit=".03"/>
                    <measurement group_id="O3" value=".03" lower_limit=".03" upper_limit=".03"/>
                    <measurement group_id="O4" value=".03" lower_limit=".03" upper_limit=".03"/>
                    <measurement group_id="O5" value=".03" lower_limit=".03" upper_limit=".03"/>
                    <measurement group_id="O6" value=".03" lower_limit=".03" upper_limit=".03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".03" lower_limit=".03" upper_limit=".03"/>
                    <measurement group_id="O2" value=".03" lower_limit=".03" upper_limit=".03"/>
                    <measurement group_id="O3" value=".03" lower_limit=".03" upper_limit=".03"/>
                    <measurement group_id="O4" value=".03" lower_limit=".03" upper_limit=".03"/>
                    <measurement group_id="O5" value=".03" lower_limit=".03" upper_limit=".04"/>
                    <measurement group_id="O6" value=".03" lower_limit=".03" upper_limit=".03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".04" lower_limit=".03" upper_limit=".05"/>
                    <measurement group_id="O2" value=".25" lower_limit=".14" upper_limit=".45"/>
                    <measurement group_id="O3" value=".23" lower_limit=".14" upper_limit=".39"/>
                    <measurement group_id="O4" value=".10" lower_limit=".07" upper_limit=".14"/>
                    <measurement group_id="O5" value=".08" lower_limit=".05" upper_limit=".11"/>
                    <measurement group_id="O6" value=".67" lower_limit=".48" upper_limit=".95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".11" lower_limit=".07" upper_limit=".16"/>
                    <measurement group_id="O2" value=".77" lower_limit=".49" upper_limit="1.20"/>
                    <measurement group_id="O3" value=".80" lower_limit=".54" upper_limit="1.17"/>
                    <measurement group_id="O4" value=".12" lower_limit=".08" upper_limit=".16"/>
                    <measurement group_id="O5" value=".43" lower_limit=".30" upper_limit=".63"/>
                    <measurement group_id="O6" value="1.02" lower_limit=".80" upper_limit="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".36" lower_limit=".25" upper_limit=".52"/>
                    <measurement group_id="O2" value="2.92" lower_limit="1.90" upper_limit="4.48"/>
                    <measurement group_id="O3" value=".75" lower_limit=".50" upper_limit="1.11"/>
                    <measurement group_id="O4" value="2.98" lower_limit="2.08" upper_limit="4.27"/>
                    <measurement group_id="O5" value=".84" lower_limit=".60" upper_limit="1.16"/>
                    <measurement group_id="O6" value="1.06" lower_limit=".82" upper_limit="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".55" lower_limit=".45" upper_limit=".68"/>
                    <measurement group_id="O2" value="4.26" lower_limit="3.20" upper_limit="5.66"/>
                    <measurement group_id="O3" value=".69" lower_limit=".47" upper_limit="1.02"/>
                    <measurement group_id="O4" value="6.73" lower_limit="5.19" upper_limit="8.72"/>
                    <measurement group_id="O5" value=".94" lower_limit=".73" upper_limit="1.21"/>
                    <measurement group_id="O6" value=".94" lower_limit=".72" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".45" lower_limit=".36" upper_limit=".56"/>
                    <measurement group_id="O2" value="3.38" lower_limit="2.58" upper_limit="4.43"/>
                    <measurement group_id="O3" value=".60" lower_limit=".41" upper_limit=".88"/>
                    <measurement group_id="O4" value="5.30" lower_limit="4.12" upper_limit="6.81"/>
                    <measurement group_id="O5" value=".79" lower_limit=".61" upper_limit="1.03"/>
                    <measurement group_id="O6" value=".84" lower_limit=".64" upper_limit="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".32" lower_limit=".25" upper_limit=".41"/>
                    <measurement group_id="O2" value="2.36" lower_limit="1.83" upper_limit="3.06"/>
                    <measurement group_id="O3" value=".44" lower_limit=".29" upper_limit=".64"/>
                    <measurement group_id="O4" value="3.42" lower_limit="2.63" upper_limit="4.43"/>
                    <measurement group_id="O5" value=".59" lower_limit=".45" upper_limit=".78"/>
                    <measurement group_id="O6" value=".69" lower_limit=".53" upper_limit=".89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".20" lower_limit=".15" upper_limit=".26"/>
                    <measurement group_id="O2" value="1.48" lower_limit="1.17" upper_limit="1.87"/>
                    <measurement group_id="O3" value=".30" lower_limit=".20" upper_limit=".45"/>
                    <measurement group_id="O4" value="2.08" lower_limit="1.59" upper_limit="2.71"/>
                    <measurement group_id="O5" value=".42" lower_limit=".30" upper_limit=".59"/>
                    <measurement group_id="O6" value=".53" lower_limit=".40" upper_limit=".70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".05" lower_limit=".04" upper_limit=".07"/>
                    <measurement group_id="O2" value=".37" lower_limit=".28" upper_limit=".48"/>
                    <measurement group_id="O3" value=".12" lower_limit=".09" upper_limit=".17"/>
                    <measurement group_id="O4" value=".34" lower_limit=".24" upper_limit=".46"/>
                    <measurement group_id="O5" value=".12" lower_limit=".08" upper_limit=".16"/>
                    <measurement group_id="O6" value=".23" lower_limit=".17" upper_limit=".32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 394</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".04" lower_limit=".03" upper_limit=".04"/>
                    <measurement group_id="O2" value=".14" lower_limit=".10" upper_limit=".20"/>
                    <measurement group_id="O3" value=".10" lower_limit=".07" upper_limit=".13"/>
                    <measurement group_id="O4" value=".09" lower_limit=".07" upper_limit=".12"/>
                    <measurement group_id="O5" value=".05" lower_limit=".04" upper_limit=".07"/>
                    <measurement group_id="O6" value=".16" lower_limit=".11" upper_limit=".23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TNA Effective Dilution Resulting in 50% Neutralization (ED50) Antibody Levels</title>
        <description>A higher TNA ED50 antibody level means a better immune response to the vaccine.</description>
        <time_frame>Days 1, 8, 22, 29, 36, 43, 50, 64, 85, 181, and 394</time_frame>
        <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>TNA Effective Dilution Resulting in 50% Neutralization (ED50) Antibody Levels</title>
          <description>A higher TNA ED50 antibody level means a better immune response to the vaccine.</description>
          <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="16.5" upper_limit="16.5"/>
                    <measurement group_id="O2" value="16.5" lower_limit="16.5" upper_limit="16.5"/>
                    <measurement group_id="O3" value="16.5" lower_limit="16.5" upper_limit="16.5"/>
                    <measurement group_id="O4" value="16.5" lower_limit="16.5" upper_limit="16.5"/>
                    <measurement group_id="O5" value="16.5" lower_limit="16.5" upper_limit="16.5"/>
                    <measurement group_id="O6" value="16.5" lower_limit="16.5" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="16.5" upper_limit="16.5"/>
                    <measurement group_id="O2" value="16.5" lower_limit="16.5" upper_limit="16.5"/>
                    <measurement group_id="O3" value="16.5" lower_limit="16.5" upper_limit="16.5"/>
                    <measurement group_id="O4" value="16.5" lower_limit="16.5" upper_limit="16.5"/>
                    <measurement group_id="O5" value="17.18" lower_limit="15.83" upper_limit="18.66"/>
                    <measurement group_id="O6" value="16.5" lower_limit="16.5" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.13" lower_limit="16.84" upper_limit="24.06"/>
                    <measurement group_id="O2" value="136.20" lower_limit="77.04" upper_limit="240.78"/>
                    <measurement group_id="O3" value="122.26" lower_limit="73.04" upper_limit="204.66"/>
                    <measurement group_id="O4" value="52.24" lower_limit="35.89" upper_limit="76.03"/>
                    <measurement group_id="O5" value="35.66" lower_limit="24.05" upper_limit="52.87"/>
                    <measurement group_id="O6" value="322.78" lower_limit="228.43" upper_limit="456.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.88" lower_limit="36.12" upper_limit="83.36"/>
                    <measurement group_id="O2" value="410.47" lower_limit="263.48" upper_limit="639.47"/>
                    <measurement group_id="O3" value="411.94" lower_limit="280.68" upper_limit="604.59"/>
                    <measurement group_id="O4" value="63.02" lower_limit="44.68" upper_limit="88.88"/>
                    <measurement group_id="O5" value="208.90" lower_limit="144.37" upper_limit="302.28"/>
                    <measurement group_id="O6" value="501.88" lower_limit="391.96" upper_limit="642.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.97" lower_limit="130.74" upper_limit="270.25"/>
                    <measurement group_id="O2" value="1557.95" lower_limit="1030.38" upper_limit="2355.64"/>
                    <measurement group_id="O3" value="389.79" lower_limit="262.37" upper_limit="579.07"/>
                    <measurement group_id="O4" value="1548.57" lower_limit="1102.91" upper_limit="2174.32"/>
                    <measurement group_id="O5" value="410.11" lower_limit="297.17" upper_limit="565.97"/>
                    <measurement group_id="O6" value="519.81" lower_limit="397.84" upper_limit="679.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299.59" lower_limit="243.47" upper_limit="368.64"/>
                    <measurement group_id="O2" value="2135.14" lower_limit="1605.51" upper_limit="2839.48"/>
                    <measurement group_id="O3" value="361.30" lower_limit="245.67" upper_limit="531.35"/>
                    <measurement group_id="O4" value="3490.12" lower_limit="2737.94" upper_limit="4448.95"/>
                    <measurement group_id="O5" value="495.07" lower_limit="386.91" upper_limit="633.48"/>
                    <measurement group_id="O6" value="497.77" lower_limit="384.03" upper_limit="645.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.88" lower_limit="201.26" upper_limit="312.73"/>
                    <measurement group_id="O2" value="1658.94" lower_limit="1265.22" upper_limit="2175.19"/>
                    <measurement group_id="O3" value="315.10" lower_limit="214.65" upper_limit="462.54"/>
                    <measurement group_id="O4" value="2600.22" lower_limit="2035.57" upper_limit="3321.51"/>
                    <measurement group_id="O5" value="414.59" lower_limit="317.69" upper_limit="541.06"/>
                    <measurement group_id="O6" value="435.56" lower_limit="331.22" upper_limit="572.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.31" lower_limit="145.92" upper_limit="232.80"/>
                    <measurement group_id="O2" value="1240.66" lower_limit="976.70" upper_limit="1575.97"/>
                    <measurement group_id="O3" value="248.04" lower_limit="168.46" upper_limit="365.21"/>
                    <measurement group_id="O4" value="1771.46" lower_limit="1386.67" upper_limit="2263.02"/>
                    <measurement group_id="O5" value="321.15" lower_limit="241.54" upper_limit="427.00"/>
                    <measurement group_id="O6" value="363.05" lower_limit="279.48" upper_limit="471.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.20" lower_limit="63.60" upper_limit="114.11"/>
                    <measurement group_id="O2" value="650.14" lower_limit="511.93" upper_limit="825.65"/>
                    <measurement group_id="O3" value="136.72" lower_limit="93.76" upper_limit="199.38"/>
                    <measurement group_id="O4" value="902.39" lower_limit="689.72" upper_limit="1180.63"/>
                    <measurement group_id="O5" value="181.14" lower_limit="130.24" upper_limit="251.92"/>
                    <measurement group_id="O6" value="224.09" lower_limit="171.05" upper_limit="293.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.55" lower_limit="20.08" upper_limit="32.51"/>
                    <measurement group_id="O2" value="163.46" lower_limit="124.59" upper_limit="214.46"/>
                    <measurement group_id="O3" value="55.87" lower_limit="40.37" upper_limit="77.31"/>
                    <measurement group_id="O4" value="151.24" lower_limit="111.24" upper_limit="205.61"/>
                    <measurement group_id="O5" value="55.17" lower_limit="39.33" upper_limit="77.39"/>
                    <measurement group_id="O6" value="108.67" lower_limit="80.46" upper_limit="146.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 394</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.29" lower_limit="16.52" upper_limit="20.24"/>
                    <measurement group_id="O2" value="74.48" lower_limit="52.50" upper_limit="105.68"/>
                    <measurement group_id="O3" value="49.63" lower_limit="35.44" upper_limit="69.49"/>
                    <measurement group_id="O4" value="50.29" lower_limit="37.22" upper_limit="67.97"/>
                    <measurement group_id="O5" value="27.46" lower_limit="20.16" upper_limit="37.39"/>
                    <measurement group_id="O6" value="76.66" lower_limit="52.84" upper_limit="111.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Enzyme-linked Immunosorbent Assay (ELISA) Anti-protective Antigen (Anti-PA) Immunoglobulin G (IgG) Antibody Levels</title>
        <description>A higher ELISA anti-PA IgG antibody level means a better immune response to the vaccine.</description>
        <time_frame>Days 1, 8, 22, 29, 36, 43, 50, 64, 85, 181, and 394</time_frame>
        <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Enzyme-linked Immunosorbent Assay (ELISA) Anti-protective Antigen (Anti-PA) Immunoglobulin G (IgG) Antibody Levels</title>
          <description>A higher ELISA anti-PA IgG antibody level means a better immune response to the vaccine.</description>
          <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" lower_limit="4.64" upper_limit="4.64"/>
                    <measurement group_id="O2" value="4.78" lower_limit="4.49" upper_limit="5.09"/>
                    <measurement group_id="O3" value="4.64" lower_limit="4.64" upper_limit="4.64"/>
                    <measurement group_id="O4" value="4.91" lower_limit="4.51" upper_limit="5.34"/>
                    <measurement group_id="O5" value="4.64" lower_limit="4.64" upper_limit="4.64"/>
                    <measurement group_id="O6" value="4.64" lower_limit="4.64" upper_limit="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" lower_limit="4.64" upper_limit="4.64"/>
                    <measurement group_id="O2" value="4.77" lower_limit="4.50" upper_limit="5.07"/>
                    <measurement group_id="O3" value="4.64" lower_limit="4.64" upper_limit="4.64"/>
                    <measurement group_id="O4" value="4.96" lower_limit="4.49" upper_limit="5.48"/>
                    <measurement group_id="O5" value="4.78" lower_limit="4.49" upper_limit="5.09"/>
                    <measurement group_id="O6" value="4.64" lower_limit="4.64" upper_limit="4.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" lower_limit="4.78" upper_limit="7.68"/>
                    <measurement group_id="O2" value="37.28" lower_limit="22.32" upper_limit="62.27"/>
                    <measurement group_id="O3" value="40.33" lower_limit="25.68" upper_limit="63.36"/>
                    <measurement group_id="O4" value="10.26" lower_limit="7.19" upper_limit="14.62"/>
                    <measurement group_id="O5" value="19.61" lower_limit="12.91" upper_limit="29.77"/>
                    <measurement group_id="O6" value="80.66" lower_limit="58.31" upper_limit="111.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.84" lower_limit="19.12" upper_limit="46.58"/>
                    <measurement group_id="O2" value="124.04" lower_limit="84.60" upper_limit="181.85"/>
                    <measurement group_id="O3" value="138.17" lower_limit="97.23" upper_limit="196.34"/>
                    <measurement group_id="O4" value="11.98" lower_limit="8.29" upper_limit="17.31"/>
                    <measurement group_id="O5" value="106.64" lower_limit="75.80" upper_limit="150.02"/>
                    <measurement group_id="O6" value="139.82" lower_limit="112.50" upper_limit="173.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.98" lower_limit="52.39" upper_limit="110.20"/>
                    <measurement group_id="O2" value="347.86" lower_limit="243.34" upper_limit="497.29"/>
                    <measurement group_id="O3" value="134.15" lower_limit="94.10" upper_limit="191.25"/>
                    <measurement group_id="O4" value="232.20" lower_limit="165.79" upper_limit="325.21"/>
                    <measurement group_id="O5" value="180.58" lower_limit="131.55" upper_limit="247.90"/>
                    <measurement group_id="O6" value="135.86" lower_limit="109.84" upper_limit="168.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.55" lower_limit="91.81" upper_limit="153.09"/>
                    <measurement group_id="O2" value="493.50" lower_limit="382.46" upper_limit="636.78"/>
                    <measurement group_id="O3" value="122.18" lower_limit="87.02" upper_limit="171.55"/>
                    <measurement group_id="O4" value="504.56" lower_limit="394.48" upper_limit="645.35"/>
                    <measurement group_id="O5" value="211.41" lower_limit="164.67" upper_limit="271.43"/>
                    <measurement group_id="O6" value="120.44" lower_limit="96.47" upper_limit="150.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.39" lower_limit="77.25" upper_limit="130.45"/>
                    <measurement group_id="O2" value="417.04" lower_limit="323.71" upper_limit="537.28"/>
                    <measurement group_id="O3" value="104.99" lower_limit="74.97" upper_limit="147.03"/>
                    <measurement group_id="O4" value="418.50" lower_limit="330.55" upper_limit="529.85"/>
                    <measurement group_id="O5" value="170.18" lower_limit="131.18" upper_limit="220.79"/>
                    <measurement group_id="O6" value="107.84" lower_limit="86.93" upper_limit="133.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.71" lower_limit="53.58" upper_limit="90.70"/>
                    <measurement group_id="O2" value="334.57" lower_limit="259.73" upper_limit="430.97"/>
                    <measurement group_id="O3" value="80.74" lower_limit="58.90" upper_limit="110.69"/>
                    <measurement group_id="O4" value="312.36" lower_limit="246.20" upper_limit="396.30"/>
                    <measurement group_id="O5" value="124.79" lower_limit="95.68" upper_limit="162.77"/>
                    <measurement group_id="O6" value="81.47" lower_limit="65.02" upper_limit="102.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.50" lower_limit="33.31" upper_limit="56.82"/>
                    <measurement group_id="O2" value="208.58" lower_limit="162.53" upper_limit="267.69"/>
                    <measurement group_id="O3" value="48.40" lower_limit="35.84" upper_limit="65.36"/>
                    <measurement group_id="O4" value="195.23" lower_limit="154.55" upper_limit="246.62"/>
                    <measurement group_id="O5" value="67.78" lower_limit="51.26" upper_limit="89.63"/>
                    <measurement group_id="O6" value="50.33" lower_limit="40.58" upper_limit="62.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.43" lower_limit="7.16" upper_limit="12.42"/>
                    <measurement group_id="O2" value="42.60" lower_limit="32.44" upper_limit="55.92"/>
                    <measurement group_id="O3" value="11.70" lower_limit="8.86" upper_limit="15.44"/>
                    <measurement group_id="O4" value="36.95" lower_limit="28.22" upper_limit="48.37"/>
                    <measurement group_id="O5" value="17.43" lower_limit="12.76" upper_limit="23.81"/>
                    <measurement group_id="O6" value="17.90" lower_limit="13.83" upper_limit="23.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 394</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76" lower_limit="4.51" upper_limit="5.02"/>
                    <measurement group_id="O2" value="12.52" lower_limit="9.09" upper_limit="17.23"/>
                    <measurement group_id="O3" value="7.09" lower_limit="5.74" upper_limit="8.76"/>
                    <measurement group_id="O4" value="9.24" lower_limit="7.30" upper_limit="11.70"/>
                    <measurement group_id="O5" value="6.74" lower_limit="5.14" upper_limit="8.83"/>
                    <measurement group_id="O6" value="10.33" lower_limit="8.17" upper_limit="13.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Based on TNA NF50, Defined as a TNA NF50 Antibody Level ≥0.56</title>
        <description>The percentage of participants achieving seroprotection based on TNA NF50 antibody level. A 70% probability of survival was associated with a TNA NF50 level of 0.56 in rabbits exposed to Bacillus anthracis, the bacteria that causes anthrax.</description>
        <time_frame>Days 1, 8, 22, 29, 36, 43, 50, 85, 181, and 394</time_frame>
        <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Based on TNA NF50, Defined as a TNA NF50 Antibody Level ≥0.56</title>
          <description>The percentage of participants achieving seroprotection based on TNA NF50 antibody level. A 70% probability of survival was associated with a TNA NF50 level of 0.56 in rabbits exposed to Bacillus anthracis, the bacteria that causes anthrax.</description>
          <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 394</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Based on TNA NF50, Defined as a ≥4-fold Increase Over Pre-vaccination Levels, or a ≥4-fold Increase Over the Lower Limit of Quantification (LLOQ) if the Pre-vaccination Value is Below the LLOQ</title>
        <description>The percentage of subjects obtaining seroconversion based on TNA NF50 antibody levels. Seroconversion represents the minimum intended effect of vaccination.</description>
        <time_frame>Days 8, 22, 29, 36, 43, 50, 64, 85, 181, and 394</time_frame>
        <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Based on TNA NF50, Defined as a ≥4-fold Increase Over Pre-vaccination Levels, or a ≥4-fold Increase Over the Lower Limit of Quantification (LLOQ) if the Pre-vaccination Value is Below the LLOQ</title>
          <description>The percentage of subjects obtaining seroconversion based on TNA NF50 antibody levels. Seroconversion represents the minimum intended effect of vaccination.</description>
          <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 394</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Based on TNA ED50, Defined as a ≥4-fold Increase Over Pre-vaccination Levels, or a ≥4-fold Increase Over the Lower Limit of Quantification (LLOQ) if the Pre-vaccination Value is Below the LLOQ</title>
        <description>The percentage of subjects obtaining seroconversion based on TNA ED50 antibody levels. Seroconversion represents the minimum intended effect of vaccination.</description>
        <time_frame>Days 8, 22, 29, 36, 43, 50, 64, 85, 181, and 394</time_frame>
        <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Based on TNA ED50, Defined as a ≥4-fold Increase Over Pre-vaccination Levels, or a ≥4-fold Increase Over the Lower Limit of Quantification (LLOQ) if the Pre-vaccination Value is Below the LLOQ</title>
          <description>The percentage of subjects obtaining seroconversion based on TNA ED50 antibody levels. Seroconversion represents the minimum intended effect of vaccination.</description>
          <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 394</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Based on ELISA Anti-PA IgG, Defined as a ≥4-fold Increase Over Pre-vaccination Levels, or a ≥4-fold Increase Over the Lower Limit of Quantification (LLOQ) if the Pre-vaccination Value is Below the LLOQ</title>
        <description>The percentage of subjects obtaining seroconversion based on ELISA anti-PA IgG antibody levels. Seroconversion represents the minimum intended effect of vaccination.</description>
        <time_frame>Days 8, 22, 29, 36, 43, 50, 64, 85, 181, and 394</time_frame>
        <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Age ≥ 66 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O2">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
          </group>
          <group group_id="O3">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
          <group group_id="O4">
            <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
          </group>
          <group group_id="O5">
            <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
            <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
          </group>
          <group group_id="O6">
            <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
            <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Based on ELISA Anti-PA IgG, Defined as a ≥4-fold Increase Over Pre-vaccination Levels, or a ≥4-fold Increase Over the Lower Limit of Quantification (LLOQ) if the Pre-vaccination Value is Below the LLOQ</title>
          <description>The percentage of subjects obtaining seroconversion based on ELISA anti-PA IgG antibody levels. Seroconversion represents the minimum intended effect of vaccination.</description>
          <population>Immunogenicity per protocol population (IPPP) includes all randomized participants who received a full dose of the correct vaccine at Days 1, 15, and 29 within the protocol specified windows, had determinate assay results at Day 64 (within window), and had no major protocol deviations that may have impacted immunogenicity assessments.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="42"/>
                <count group_id="O6" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="41"/>
                    <measurement group_id="O6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 181</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 394</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study vaccine through Day 394.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Age ≥ 66 Years: BioThrax (Day1, Day 15, Day 29)</title>
          <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
        </group>
        <group group_id="E2">
          <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15, Day 29)</title>
          <description>Participants dosed intramuscularly (IM) on Days 1, 15, and 29 with 0.5 mL AV7909</description>
        </group>
        <group group_id="E3">
          <title>Age ≥ 66 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5mL placebo</description>
        </group>
        <group group_id="E4">
          <title>Age ≥ 66 Years: AV7909 (Day 1, Day 29) With Placebo (Day 15)</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 29 with 0.5 mL AV7909 and dosed IM on Day 15 with 0.5 mL placebo</description>
        </group>
        <group group_id="E5">
          <title>Age 18-50 Years: BioThrax (Day 1, Day 15, Day 29)</title>
          <description>Participants dosed subcutaneously (SC) on Days 1, 15, and 29 with 0.5 mL BioThrax</description>
        </group>
        <group group_id="E6">
          <title>Age 18-50 Years: AV7909 (Day 1, Day 15) With Placebo (Day 29)</title>
          <description>Participants dosed intramuscularly (IM) on Days 1 and 15 with 0.5 mL AV7909 and dosed IM on Day 29 with 0.5 mL placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="51" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" events="25" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="49"/>
                <counts group_id="E4" events="21" subjects_affected="14" subjects_at_risk="52"/>
                <counts group_id="E5" events="14" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E6" events="28" subjects_affected="21" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site discolouration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="74" subjects_affected="34" subjects_at_risk="50"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E5" events="55" subjects_affected="27" subjects_at_risk="52"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="74" subjects_affected="34" subjects_at_risk="50"/>
                <counts group_id="E2" events="22" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E4" events="14" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E5" events="57" subjects_affected="29" subjects_at_risk="52"/>
                <counts group_id="E6" events="14" subjects_affected="12" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" events="93" subjects_affected="38" subjects_at_risk="50"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E4" events="16" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E5" events="75" subjects_affected="37" subjects_at_risk="52"/>
                <counts group_id="E6" events="9" subjects_affected="8" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site movement impairment</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" events="31" subjects_affected="22" subjects_at_risk="50"/>
                <counts group_id="E3" events="17" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E5" events="30" subjects_affected="15" subjects_at_risk="52"/>
                <counts group_id="E6" events="32" subjects_affected="24" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="152" subjects_affected="44" subjects_at_risk="50"/>
                <counts group_id="E2" events="126" subjects_affected="41" subjects_at_risk="50"/>
                <counts group_id="E3" events="77" subjects_affected="36" subjects_at_risk="49"/>
                <counts group_id="E4" events="91" subjects_affected="43" subjects_at_risk="52"/>
                <counts group_id="E5" events="191" subjects_affected="49" subjects_at_risk="52"/>
                <counts group_id="E6" events="138" subjects_affected="50" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="48" subjects_affected="26" subjects_at_risk="50"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E5" events="60" subjects_affected="30" subjects_at_risk="52"/>
                <counts group_id="E6" events="7" subjects_affected="5" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="65" subjects_affected="26" subjects_at_risk="50"/>
                <counts group_id="E2" events="31" subjects_affected="21" subjects_at_risk="50"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E4" events="25" subjects_affected="15" subjects_at_risk="52"/>
                <counts group_id="E5" events="60" subjects_affected="27" subjects_at_risk="52"/>
                <counts group_id="E6" events="19" subjects_affected="13" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E6" events="8" subjects_affected="7" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="19" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E4" events="20" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E5" events="12" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E6" events="37" subjects_affected="26" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" events="41" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E3" events="16" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E4" events="26" subjects_affected="17" subjects_at_risk="52"/>
                <counts group_id="E5" events="17" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E6" events="37" subjects_affected="26" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. Data and results are owned by Sponsor. Results can be used by Institution for (a) internal non-commercial research, education and patient care, and (b) as required under applicable laws and regulations. Other uses require prior written consent of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Hollingsworth/Regulatory Operations Specialist</name_or_title>
      <organization>BARDA</organization>
      <phone>202-691-2040</phone>
      <email>Susan.Hollingsworth@hhs.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

